First-in-human study to assess the pharmacokinetics, tolerability, and safety of single-dose oxybutynin hydrochloride administered via a microprocessor-controlled intravaginal ring

References

• Adepu S, Ramakrishna S. (2021). Controlled drug delivery systems: current status and future directions. Molecules 26:1.
   Web of Science ®Google Scholar
• Ahrendt HJ, Nisand I, Bastianelli C, et al. (2006). Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone. Contraception 74:451–8.
   PubMed Web of Science ®Google Scholar
• Alexander NJ, Baker E, Kaptein M, et al. (2004). Why consider vaginal drug administration?. Fertil Steril 82:1–12.
   PubMed Web of Science ®Google Scholar
• Algorta J, Diaz M, de Benito R, et al. (2017). Pharmacokinetic bioequivalence, safety and acceptability of Ornibel(®), a new polymer composition contraceptive vaginal ring (etonogestrel/ethinylestradiol 11.00/3.474 mg) compared with Nuvaring(®) (etonogestrel/ethinylestradiol 11.7/2.7 mg). Eur J Contracept Reprod Health Care 22:429–38.
   PubMed Web of Science ®Google Scholar
• Appell RA, Chancellor MB, Zobrist RH, et al. (2003). Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin Proc 78:696–702.
   PubMed Web of Science ®Google Scholar
• Baeten JM, Palanee-Phillips T, Brown ER, et al. (2016). Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med 375:2121–32.
   PubMed Web of Science ®Google Scholar
• Bounds W, Szarewski A, Lowe D, Guillebaud J. (1993). Preliminary report of unexpected local reactions to a progestogen-releasing contraceptive vaginal ring. Eur J Obstet Gynecol Reprod Biol 48:123–5.
   PubMed Web of Science ®Google Scholar
• Boyd P, Desjardins D, Kumar S, et al. (2015). A temperature-monitoring vaginal ring for measuring adherence. PLoS One 10:e0125682.
   PubMed Web of Science ®Google Scholar
• Boyd P, Variano B, Spence P, et al. (2019). In vitro release testing methods for drug-releasing vaginal rings. J Control Release 313:54–69.
   PubMed Web of Science ®Google Scholar
• Dallal Bashi YH, McCoy CF, Murphy DJ, et al. (2019). Towards a dapivirine and levonorgestrel multipurpose vaginal ring: investigations into the reaction between levonorgestrel and addition-cure silicone elastomers. Int J Pharm 569:118574.
   PubMedGoogle Scholar
• Dallal Bashi YH, Murphy DJ, McCoy CF, et al. (2021). Silicone elastomer formulations for improved performance of a multipurpose vaginal ring releasing dapivirine and levonorgestrel. Int J Pharm X 3:100091.
   PubMedGoogle Scholar
• Davila GW. (2006). Transdermal oxybutynin in the treatment of overactive bladder. Clin Interv Aging 1:99–105.
   PubMed Web of Science ®Google Scholar
• de Jesus Antunes N, de Oliveira Filho RV, de Oliveira Ilha J, et al. (2021). Single-dose pharmacokinetics and pharmacodynamics assessment of oestriol and trimegestone containing vaginal rings in healthy women with childbearing potential. Eur J Contracept Reprod Health Care 26:184–94.
   PubMed Web of Science ®Google Scholar
• Delebecq E, Ganachaud F. (2012). ‘Looking over liquid silicone rubbers: (1) network topology vs chemical formulations. ACS Appl Mater Interfaces 4:3340–52.
   PubMed Web of Science ®Google Scholar
• Denney W, Duvvuri S, Buckeridge C. (2015). Abstracts accepted for American Conference on Pharmacometrics 2015 (ACoP6). J Pharmacokinet Pharmacodyn 42:11–107.
   Google Scholar
• Diokno AC, Lapides J. (1972). Oxybutynin: a new drug with analgesic and anticholinergic properties. J Urol 108:307–9.
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Newman DK, Sand PK, et al. (2011). Pharmacokinetics of oxybutynin chloride topical gel. Clin Drug Investig 31:559–71.
   PubMed Web of Science ®Google Scholar
• Douchamps J, Derenne F, Stockis A, et al. (1988). The pharmacokinetics of oxybutynin in man. Eur J Clin Pharmacol 35:515–20.
   PubMed Web of Science ®Google Scholar
• Drugbank. 2023. Oxybutynin. Available at: https://go.drugbank.com/drugs/DB01062. Accessed January 25, 2023.
   Google Scholar
• Duijkers IJM, Klipping C, Draeger C, et al. (2020). Ovulation inhibition with a new vaginal ring containing trimegestone. Contraception 102:237–42.
   PubMed Web of Science ®Google Scholar
• Electronic Medicines Compendium (2023). Summary of product characteristics for Oxybutynin hydrochloride tablets 2.5 mg. Available at: https://www.medicines.org.uk/emc/product/14309/smpc [accessed 2023 Feb 18].
   Google Scholar
• Flores SA, Hall CA. 2022. Atrophic vaginitis. In: StatPearls. Treasure Island (FL): StatPearls Publishing.
   Google Scholar
• Gittelman M, Weiss H, Seidman L. (2014). A phase 2, randomized, double-blind, efficacy and safety study of oxybutynin vaginal ring for alleviation of overactive bladder symptoms in women. J Urol 191:1014–21.
   PubMed Web of Science ®Google Scholar
• Gomaa E, Abu Lila AS, Hasan AA, Ghazy FS. (2018). Preparation and characterization of intravaginal vardenafil suppositories targeting a complementary treatment to boost in vitro fertilization process. Eur J Pharm Sci 111:113–20.
   PubMed Web of Science ®Google Scholar
• Gomelsky A, Dmochowski RR. (2012). Oxybutynin gel for the treatment of overactive bladder. Expert Opin Pharmacother 13:1337–43.
   PubMed Web of Science ®Google Scholar
• Gupta S, Gabrani R, Ali J, Dang S. (2011). Exploring novel approaches to vaginal drug delivery. Recent Pat Drug Deliv Formul 5:82–94.
   PubMedGoogle Scholar
• Harwood B, Mishell DRJr. (2001). Contraceptive vaginal rings. Semin Reprod Med 19:381–90.
   PubMed Web of Science ®Google Scholar
• Henriksson L, Stjernquist M, Boquist L, et al. (1996). A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging. Am J Obstet Gynecol 174:85–92.
   PubMed Web of Science ®Google Scholar
• Hoffman AS. (2008). The origins and evolution of “controlled” drug delivery systems. J Control Release 132:153–63.
   PubMed Web of Science ®Google Scholar
• Hussain A, Ahsan F. (2005). The vagina as a route for systemic drug delivery. J Control Release 103:301–13.
   PubMed Web of Science ®Google Scholar
• Iqbal Z, Dilnawaz F. (2019). Nanocarriers for vaginal drug delivery. Recent Pat Drug Deliv Formul 13:3–15.
   PubMedGoogle Scholar
• Jirschele K, Sand PK. (2013). Oxybutynin: past, present, and future. Int Urogynecol J 24:595–604.
   PubMed Web of Science ®Google Scholar
• Kennelly MJ. (2010). A comparative review of oxybutynin chloride formulations: pharmacokinetics and therapeutic efficacy in overactive bladder. Rev Urol 12:12–9.
   PubMedGoogle Scholar
• Krause P, Fuhr U, Schnitker J, et al. (2013). Pharmacokinetics of intravesical versus oral oxybutynin in healthy adults: results of an open label, randomized, prospective clinical study’. J Urol 190:1791–7.
   PubMed Web of Science ®Google Scholar
• Kretschmar M, Suleiman AA, Krause P, et al. (2021). A population pharmacokinetic model of (r)- and (s-) oxybutynin and its active metabolites after oral and intravesical administration to healthy volunteers. J Clin Pharmacol 61:961–71.
   PubMed Web of Science ®Google Scholar
• Liu AY, Dominguez Islas C, Gundacker H, et al. (2021). Phase 1 pharmacokinetics and safety study of extended duration dapivirine vaginal rings in the United States. J Int AIDS Soc 24:e25747.
   PubMed Web of Science ®Google Scholar
• López-Picado A, Lapuente O, Lete I. (2017). Efficacy and side-effects profile of the ethinylestradiol and etonogestrel contraceptive vaginal ring: a systematic review and meta-analysis. Eur J Contracept Reprod Health Care 22:131–46.
   PubMed Web of Science ®Google Scholar
• Lopez LM, Grimes DA, Gallo MF, et al. (2013). Skin patch and vaginal ring versus combined oral contraceptives for contraception. Cochrane Database Syst Rev 2013:CD003552.
   PubMedGoogle Scholar
• MacDiarmid SA. (2009). The evolution of transdermal/topical overactive bladder therapy and its benefits over oral therapy. Rev Obstet Gynecol 2:116–21.
   PubMedGoogle Scholar
• Malcolm RK, Boyd PJ, McCoy CF, Murphy DJ. (2016). Microbicide vaginal rings: technological challenges and clinical development. Adv Drug Deliv Rev 103:33–56.
   PubMed Web of Science ®Google Scholar
• Mathias NR, Hussain MA. (2010). Non-invasive systemic drug delivery: developability considerations for alternate routes of administration. J Pharm Sci 99:1–20.
   PubMed Web of Science ®Google Scholar
• Monteiro I, Guazzelli CF, Bahamondes L. (2018). Advances in contraceptive vaginal rings: what does the future hold? Expert Opin Pharmacother 19:1685–91.
   PubMed Web of Science ®Google Scholar
• Rock J, Barker RH, Bacon WB. (1947). Vaginal absorption of penicillin. Tech Pap 105:13.
   Google Scholar
• Schröder A, Levin RM, Kogan BA, et al. (2000). Absorption of oxybutynin from vaginal inserts: drug blood levels and the response of the rabbit bladder. Urology 56:1063–7.
   PubMed Web of Science ®Google Scholar
• Shewale A, Yadav AR, Ashwini SJ. (2022). Novel drug delivery systems and its future prospects. J Univ Shanghai Sci Technol 24:48–60.
   Google Scholar
• Starkman JS, Dmochowski RR. (2006). Management of overactive bladder with transdermal oxybutynin. Rev Urol 8:93–103.
   PubMedGoogle Scholar
• Staskin DR. (2003). Transdermal systems for overactive bladder: principles and practice. Rev Urol 5(Suppl 8):S26–S30.
   PubMedGoogle Scholar
• Swierzewski M, Seidman L, Dasen S, Weiss H. (2013). 565 phase 3 efficacy and safety of once-monthly oxybutynin vaginal ring delivering 4 mg/day or 6 mg/day vs placebo ring in women with urge incontinence, frequency, and urgency symptoms of overactive bladder. J Urol 189:e232.
   PubMed Web of Science ®Google Scholar
• The R Core Team. 2020. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. Available at: https://www.R-project.org [accessed 2023 Jan 18].
   Google Scholar
• Thurman AR, Chandra N, Yousefieh N, et al. (2018). Differences in local and systemic tfv pk among premenopausal versus postmenopausal women exposed to tfv 1% vaginal gel. J Acquir Immune Defic Syndr 78:82–92.
   PubMed Web of Science ®Google Scholar
• Tiboni M, Campana R, Frangipani E, Casettari L. (2021). 3D printed clotrimazole intravaginal ring for the treatment of recurrent vaginal candidiasis. Int J Pharm 596:120290.
   PubMed Web of Science ®Google Scholar
• Timmer CJ, Mulders TM. (2000). Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet 39:233–42.
   PubMed Web of Science ®Google Scholar
• Tuğcu-Demiröz F, Acartürk F, Erdoğan D. (2013). Development of long-acting bioadhesive vaginal gels of oxybutynin: formulation, in vitro and in vivo evaluations. Int J Pharm 457:25–39.
   PubMed Web of Science ®Google Scholar
• U.S. Food & Drug Administration. (2023). FDA Database: Inactive Ingredient Search for Approved Drug Products. Available at: https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm [accessed 2023 Jan 18].
   Google Scholar
• Woolfson AD, Malcolm RK, Gallagher RJ. (2003). Design of a silicone reservoir intravaginal ring for the delivery of oxybutynin. J Control Release 91:465–76.
   PubMed Web of Science ®Google Scholar
• Yamada S, Ito Y, Nishijima S, et al. (2018). Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder. Pharmacol Ther 189:130–48.
   PubMed Web of Science ®Google Scholar
• Yarker YE, Goa KL, Fitton A. (1995). Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 6:243–62.
   PubMed Web of Science ®Google Scholar
• Zobrist RH, Quan D, Thomas HM, et al. (2003). Pharmacokinetics and metabolism of transdermal oxybutynin: in vitro and in vivo performance of a novel delivery system. Pharm Res 20:103–9.
   PubMed Web of Science ®Google Scholar